Potential Anticancer Activity of Mn (II) Complexes Containing Arginine Dithiocarbamate Ligand on MCF-7 Breast Cancer Cell Lines

Overview

Journal Ann Med Surg (Lond)

Publisher Wolters Kluwer

Specialty Medical Education

Date 2020 Nov 25

PMID 33235715

Citations 7

Authors

Prihantono

Rizal Irfandi

Indah Raya

Warsinggih

Affiliations

Soon will be listed here.

Abstract

Introduction: Cancer refer to genetic changes in the DNA structure accompanied by abnormal growth of normal cells, and resulting in the death of these structures, and is a disease currently recognized as a major cause of mortality globally. Chemotherapy plays important role in breast cancer management. Non-toxic metals have been developed to replace the highly toxic cisplatin, an example being Manganese. Furthermore, Ligands have displayed great capabilities in the determination of anticancer properties, and an essential agent exploited in drug development is arginine dithiocarbamate. Therefore, this study was conducted to examine the anticancer potentials of Mn (II) arginine dithiocarbamate.

Methods: The synthesis and spectroscopic analysis of the Mn (II) Arginine dithiocarbamate complex was successfully carried out. Then, the complexes were characterized through the employment of the UV-Vis, FT-IR, as well as the melting point tests, and subsequently analyzed for anticancer activities through in vitro means. The compound was produced from UV-Vis spectrum at 246 and 385 nm wavelengths and IR spectrum at wave numbers 354-499 cm.

Results: The results revealed the cytotoxicity of Mn (II) Arginine dithiocarbamate against the MCF-7 cell line, observed from a significant change in the morphology of the cancer cells with IC50 value of 211.53 μg/mL.

Conclusion: The compound, Mn (II) Arginine dithiocarbamate has effective anticancer potentials against MCF-7 cancer cells.

Citing Articles

Integrated Molecular Docking and Experimental Analysis of Ni(II) Proline Dithiocarbamate Cytotoxicity in MCF-7 Breast Cancer Cells.

Prihantono P, Jarre S, Raya I, Santi S, Paramita K, Syamsu S Asian Pac J Cancer Prev. 2024; 25(10):3481-3487.

PMID: 39471014 PMC: 11711347. DOI: 10.31557/APJCP.2024.25.10.3481.

Design, Synthesis and Characterization of Mn(II)Cysteine-Tyrosine Dithiocarbamate Complex for against the Cancer on MCF-7 Breast Cancer Cell Line.

Arfah R, Pratiwi E, Raya I, Natsir H, Taba P, Rasyid H Asian Pac J Cancer Prev. 2024; 25(9):3251-3261.

PMID: 39342604 PMC: 11700321. DOI: 10.31557/APJCP.2024.25.9.3251.

Investigations of Ni(II)Cysteine-Tyrosine Dithiocarbamate Complex: Synthesis, Characterization, Molecular Docking, Molecular Dynamic, and Anticancer Activity on MCF-7 Breast Cancer Cell Line.

Pratiwi E, Raya I, Natsir H, Irfandi R, Taba P, Arfah R Asian Pac J Cancer Prev. 2024; 25(4):1301-1313.

PMID: 38679991 PMC: 11162741. DOI: 10.31557/APJCP.2024.25.4.1301.

Synthesis and Spectroscopic Characterization of Schiff Base Metal Complexes, Biological Activity, and Molecular Docking Studies.

Venkatesh G, Vennila P, Kaya S, Ahmed S, Sumathi P, Siva V ACS Omega. 2024; 9(7):8123-8138.

PMID: 38405527 PMC: 10882688. DOI: 10.1021/acsomega.3c08526.

Anticancer Metallocenes and Metal Complexes of Transition Elements from Groups 4 to 7.

Kostova I Molecules. 2024; 29(4).

PMID: 38398576 PMC: 10891901. DOI: 10.3390/molecules29040824.

References

Royer A, Menand M, Grimault A, Communal P . Development of automated headspace gas chromatography determination of dithiocarbamates in plant matrixes. J Agric Food Chem. 2001; 49(5):2152-8. DOI: 10.1021/jf0013196. View

Hindo S, Frezza M, Tomco D, Heeg M, Hryhorczuk L, McGarvey B . Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome. Eur J Med Chem. 2009; 44(11):4353-61. PMC: 2759842. DOI: 10.1016/j.ejmech.2009.05.019. View

Frezza M, Hindo S, Chen D, Davenport A, Schmitt S, Tomco D . Novel metals and metal complexes as platforms for cancer therapy. Curr Pharm Des. 2010; 16(16):1813-25. PMC: 3759287. DOI: 10.2174/138161210791209009. View

Frezza M, Schmitt S, Dou Q . Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy. Curr Top Med Chem. 2011; 11(23):2888-905. DOI: 10.2174/156802611798281311. View

Chen D, Milacic V, Frezza M, Dou Q . Metal complexes, their cellular targets and potential for cancer therapy. Curr Pharm Des. 2009; 15(7):777-91. DOI: 10.2174/138161209787582183. View

Buac D, Schmitt S, Ventro G, Kona F, Dou Q . Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells. Mini Rev Med Chem. 2012; 12(12):1193-201. PMC: 3651834. DOI: 10.2174/138955712802762040. View

Stratton M, Campbell P, Futreal P . The cancer genome. Nature. 2009; 458(7239):719-24. PMC: 2821689. DOI: 10.1038/nature07943. View

Prayong P, Barusrux S, Weerapreeyakul N . Cytotoxic activity screening of some indigenous Thai plants. Fitoterapia. 2008; 79(7-8):598-601. DOI: 10.1016/j.fitote.2008.06.007. View

Henderson B, Dougherty T . How does photodynamic therapy work?. Photochem Photobiol. 1992; 55(1):145-57. DOI: 10.1111/j.1751-1097.1992.tb04222.x. View

10.

Chen D, Dou Q . New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer. Expert Opin Ther Targets. 2008; 12(6):739-48. PMC: 3770296. DOI: 10.1517/14728222.12.6.739. View

11.

Orvig C, Abrams M . Medicinal inorganic chemistry: introduction. Chem Rev. 2001; 99(9):2201-4. DOI: 10.1021/cr980419w. View

12.

Galanski M . Recent Developments in the Field of Anticancer Platinum Complexes. Recent Pat Anticancer Drug Discov. 2008; 1(2):285-95. DOI: 10.2174/157489206777442287. View

13.

Kelland L . An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs. 2000; 9(6):1373-82. DOI: 10.1517/13543784.9.6.1373. View

14.

Milacic V, Fregona D, Dou Q . Gold complexes as prospective metal-based anticancer drugs. Histol Histopathol. 2007; 23(1):101-8. DOI: 10.14670/HH-23.101. View

15.

Adjiri A . DNA Mutations May Not Be the Cause of Cancer. Oncol Ther. 2017; 5(1):85-101. PMC: 5488117. DOI: 10.1007/s40487-017-0047-1. View

16.

Korde A, Satpati D, Mathur A, Mallia M, Banerjee S, Kothari K . 99mTc-labeling of colchicine using [99mTc(CO)3(H2O)3]+ and [99mTc triple bond N]2+ core for the preparation of potential tumor-targeting agents. Bioorg Med Chem. 2005; 14(3):793-9. DOI: 10.1016/j.bmc.2005.09.006. View

17.

Zoroddu M, Aaseth J, Crisponi G, Medici S, Peana M, Nurchi V . The essential metals for humans: a brief overview. J Inorg Biochem. 2019; 195:120-129. DOI: 10.1016/j.jinorgbio.2019.03.013. View

18.

Wang D, Lippard S . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. DOI: 10.1038/nrd1691. View

19.

Yang L, Tan J, Wang B, Zhu L . Synthesis, characterization, and anti-cancer activity of emodin-Mn(II) metal complex. Chin J Nat Med. 2015; 12(12):937-42. DOI: 10.1016/S1875-5364(14)60137-0. View

20.

Chen D, Peng F, Cui Q, Daniel K, Orlu S, Liu J . Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosci. 2005; 10:2932-9. DOI: 10.2741/1749. View